
Profitability, historical returns, and peer comparisons.
According to Edgewise Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 130.43%. This represents a change of 1.24% compared to the average of 9.77% of the last 4 quarters.
The mean historical ROE of Edgewise Therapeutics, Inc. over the last ten years is -2.93%. The current 130.43% ROE has changed -4558.02% with respect to the historical average. Over the past ten years (40 quarters), EWTX's ROE was at its highest in in the September 2026 quarter at 71.43%. The ROE was at its lowest in in the March 2020 quarter at -13.61%.
Average
-2.93%
Median
-19.51%
Minimum
-32.13%
Maximum
56.29%
Discovering the peaks and valleys of Edgewise Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 61.03%
Maximum Annual ROE = 56.29%
Minimum Annual Increase = -130.58%
Minimum Annual ROE = -32.13%
| Year | ROE | Change |
|---|---|---|
| 2025 | -32.13% | 10.26% |
| 2024 | -29.14% | -7.25% |
| 2023 | -31.42% | 61.03% |
| 2022 | -19.51% | 25.03% |
| 2021 | -15.60% | -130.58% |
| 2020 | 51.03% | -9.34% |
The current ROE of Edgewise Therapeutics, Inc. (EWTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-30.89%
5-year avg
-25.56%
10-year avg
-2.93%
Edgewise Therapeutics, Inc.’s ROE is greater than Dyne Therapeutics, Inc. (-64.30%), greater than Solid Biosciences Inc. (-67.78%), greater than Sarepta Therapeutics, Inc. (-9.96%), less than PTC Therapeutics, Inc. (57.10%), greater than Capricor Therapeutics, Inc. (-56.60%), greater than Entrada Therapeutics, Inc. (-57.61%), greater than PepGen Inc. (-51.01%), greater than Stoke Therapeutics, Inc. (-67.30%), greater than Larimar Therapeutics, Inc. (-137.39%),
| Company | ROE | Market cap |
|---|---|---|
| -64.30% | $3.46B | |
| -67.78% | $699.11M | |
| -9.96% | $2.01B | |
| 57.10% | $5.76B | |
| -56.60% | $516.57M | |
| -57.61% | $197.02M | |
| -51.01% | $169.46M | |
| -67.30% | $1.77B | |
| -137.39% | $286.72M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Edgewise Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Edgewise Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Edgewise Therapeutics, Inc.'s ROE?
How is the ROE calculated for Edgewise Therapeutics, Inc. (EWTX)?
What is the highest ROE for Edgewise Therapeutics, Inc. (EWTX)?
What is the 3-year average ROE for Edgewise Therapeutics, Inc. (EWTX)?
What is the 5-year average ROE for Edgewise Therapeutics, Inc. (EWTX)?
How does the current ROE for Edgewise Therapeutics, Inc. (EWTX) compare to its historical average?